FDA

Nine UK universities have been chosen to form the newly established NIHR Maternity Disparities Consortium, devoted to addressing inequalities in maternity care outcomes. This group will conduct research targeting disparities before, during, and after pregnancy. The consortium is also dedicated […]

Valneva SE, a specialized vaccine producer, has put forward a submission to the US Food and Drug Administration (FDA) to widen the application of its chikungunya vaccine, IXCHIQ. Currently approved for adults, Valneva aims to include the 12 to 17-year-old

Exelixis, an innovative leader in oncology striving to revolutionize cancer care with next-gen therapies, recently announced that the United States Food and Drug Administration (FDA) has confirmed their supplemental New Drug Application (sNDA) for Cabozantinib (Cabometyx) will be reviewed at

PTC Therapeutics, Inc., an international biopharmaceutical company dedicated to the innovation, development, and marketing of clinically unique medicines, announced that the phase 2 CardinALS study, a global and placebo-controlled trial, failed to meet its main goal of slowing ALS disease

Idorsia Ltd has revealed entering into confidential talks with an unidentified party to potentially secure global rights to aprocitentan. As part of this negotiation, Idorsia will receive an exclusivity payment of $35 million, extending its financial runway until 2025. The

The World Health Organization (WHO) and affiliates have announced a selection of 10 initiatives that will each receive close to USD $2 million in funding to enhance pathogen genomic surveillance capabilities. This funding initiative, established by the International Pathogen Surveillance

Lexicon Pharmaceuticals, a biopharmaceutical entity dedicated to developing transformative medicines, has finalized the patient enrollment process for their PROGRESS study. This Phase 2b trial evaluates LX9211, an innovative orally-administered selective small molecule inhibitor targeting adaptor-associated kinase 1 (AAK1), specifically for

**VectorBuilder**, renowned for its comprehensive gene delivery services, and **Sartorius**, a prominent international partner in life sciences and biopharmaceuticals, have formalized a strategic collaboration agreement. This partnership aims to enhance gene vector and mRNA bioprocess services, expediting innovative biopharmaceutical projects

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a subsidiary under Kelun Pharmaceutical, renowned for its dedication to the research, development, production, commercialization, and international partnership of novel biological and small molecule pharmaceuticals, has announced its receipt of marketing approval in China from

Novartis revealed that the European Commission has endorsed Kisqali (ribociclib) alongside an aromatase inhibitor for the adjuvant management of hormone receptor (HR)-positive, HER2-negative early breast cancer at elevated risk of recurrence. This endorsement arises from the pivotal phase III NATALEE